Practical Insight for Administering BsAbs in A Community Setting

In part 1 of this mini video series, John M. Burke, MD, provides practical tips he has learned from his experience with administering mosunetuzumab (Lunsumio) in a community setting. Mosunetuzumab is a bispecific antibody therapy (BsAbs) with an approved use for adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.¹

Burke, hematologist and medical oncologist Rocky Mountain Cancer Centers,

Associate Chair US Oncology Hematology Research Program, Aurora, Colorado, breaks down his insights into 13 tips that any clinician can apply into their practice, regardless of what BsAbs they decide to offer in their clinic.

“What we did when we first implemented this into the practice was to use mosunetuzumab as part of a clinical trial,” Burke explains regarding his experience. “If you have the opportunity to do that it is a nice way to start using BsAbs because you have the guidance of the sponsor and materials to educate your patient.”

For those that may not have the opportunity to be part of a clinical trial, Burke proceeds with a step-by-step process. Burke emphasizes that the first practical step is to educate oneself on the potential adverse events associated with the specific BsAbs you plan to implement into your practice.

Following this, it is crucial to educate your team of nurses, other staff members, and partners, as well as the staff at the hospital where you may need to admit patients.

For the full list of tips from Burke, see both videos in this series (part 1 and part 2).

Reference

FDA D.I.S.C.O. burst edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. News release. FDA. January 19, 2023. Accessed March 28, 2025. https://tinyurl.com/33eym9w3